Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chauhan D et al. – Although pDCs are resistant to novel therapies, targeting Toll–like receptors with CpG oligodeoxynucleotides both restores pDC immune function and abrogates pDC–induced MM cell growth. Our study therefore validates targeting pDC–MM interactions as a therapeutic strategy to overcome drug resistance in MM.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address